OFFER PATIENTS A CHOICE

THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY |For Patients

Tolerability: General and Elderly Populations

91%

of patients IN ONE PIVOTAL TRIAL rated sutab^® as tolerable to very easy to consume^3*

Patient Preference Data³

How was your overall experience?

72%

said it was good or excellent

How easy was it to take SUTAB^®?

65%

said it was easy to very easy

How did SUTAB^® compare with other preps you’ve taken?

65%

said it was better

Fifty-two percent of all SUTAB^® and MoviPrep^® patients reported at least one selected gastrointestinal adverse reaction. More SUTAB^® patients reported experiencing nausea and vomiting than the competitor, with ≤1% of these reports considered severe.^2† Four percent of SUTAB^® patients reported they had a bad preparation experience, 3% reported that the prep was very difficult to consume, and 15% said it was worse than their prior bowel prep experience.³

Would you request SUTAB^® again?

78%

of patients in one pivotal trial would request it for a future colonoscopy ³^*

^*Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation.

^†Patients were queried for selected gastrointestinal adverse reactions of abdominal pain, abdominal distension, nausea, and vomiting following completion of study drug, rating the intensity as mild, moderate, or severe.^2,3

IN ALL GROUPS, MOST SYMPTOMS WERE MILD^2,3

Study 1: SUTAB^® and MoviPrep^® GI Symptoms by Severity

Solicited
Symptoms^*

SUTAB^® (N=281)

MoviPrep^® (N=271)

% Nausea

Mild
Moderate
Severe

48%

% Overall^†

% by Symptom^‡

35

71

13

27

1

2

26%

% Overall^†

% by Symptom^‡

20

77

6

23

0

0

% Abdominal
distension

Mild
Moderate
Severe

29%

% Overall^†

% by Symptom^‡

21

68

9

30

0

1

22%

% Overall^†

% by Symptom^‡

16

71

6

29

0

0

% Vomiting

Mild
Moderate
Severe

23%

% Overall^†

% by Symptom^‡

11

48

12

52

0

0

5%

% Overall^†

% by Symptom^‡

3

46

3

54

0

0

% Upper
abdominal pain

Mild
Moderate
Severe

16%

% Overall^†

% by Symptom^‡

11

65

6

35

0

0

18%

% Overall^†

% by Symptom^‡

13

71

6

29

0

0

This chart is offered as a side-by-side comparison based on the product labels. Azurity does not confirm other product's labels.

^*During Studies 1 and 2, patients were queried for selected GI adverse reactions using a standard questionnaire, following completion of study prep.

^†Proportion of subjects reporting a specific symptom/severity out of all subjects who took that prep (N).³

^‡Proportion of subjects reporting a specific severity out of those that reported that specific symptom.²

MoviPrep^® is a registered trademark of Velinor AG.

Symptom definitions^2,3

Mild/barely noticeable: Does not influence functioning, causing no limitations of usual activities

Moderate: Makes participant uncomfortable, influences functioning, causing some limitations of usual activities

Severe: Severe discomfort, treatment needed, severe and undesirable, causing inability to carry out usual activities

SUTAB^® scored lower (worse) than the comparator in the symptom-rating categories for nausea and vomiting^2,3
Of the 471 patients who received SUTAB^® in pivotal clinical trials²:

— 32% (n=150) were 65 years of age or older

— 5% (n=25) were 75 years of age or older
No differences in safety or effectiveness of SUTAB^® were observed between geriatric and younger patients²

Study 2: SUTAB^® and Prepopik^® GI Symptoms by Severity

Solicited
Symptoms^*

SUTAB^® (N=190)

Prepopik^® (N=199)

% Nausea

Mild
Moderate
Severe

52%

% Overall^†

% by Symptom^‡

39

74

11

20

3

6

18%

% Overall^†

% by Symptom^‡

17

94

1

6

0

0

% Abdominal
distension

Mild
Moderate
Severe

34%

% Overall^†

% by Symptom^‡

25

73

9

27

0

0

15%

% Overall^†

% by Symptom^‡

11

69

5

31

0

0

% Vomiting

Mild
Moderate
Severe

16%

% Overall^†

% by Symptom^‡

9

53

8

47

0

0

2%

% Overall^†

% by Symptom^‡

1

33

1

67

0

0

% Upper
abdominal pain

Mild
Moderate
Severe

23%

% Overall^†

% by Symptom^‡

18

82

4

16

1

2

13%

% Overall^†

% by Symptom^‡

13

100

1

0

1

0

This chart is offered as a side-by-side comparison based on the product labels. Azurity does not confirm other product's labels.

^*During Studies 1 and 2, patients were queried for selected GI adverse reactions using a standard questionnaire, following completion of study prep.

^†Proportion of subjects reporting a specific symptom/severity out of all subjects who took that prep (N).³

^‡Proportion of subjects reporting a specific severity out of those that reported that specific symptom.²

Prepopik^® is a registered trademark of Ferring B.V.

Symptom definitions^2,3

Mild/barely noticeable: Does not influence functioning, causing no limitations of usual activities

Moderate: Makes participant uncomfortable, influences functioning, causing some limitations of usual activities

Severe: Severe discomfort, treatment needed, severe and undesirable, causing inability to carry out usual activities

SUTAB^® scored lower (worse) than the comparator in the symptom-rating categories for nausea, abdominal distention, vomiting, and upper abdominal pain^2,3
Of the 471 patients who received SUTAB^® in pivotal clinical trials²:

— 32% (n=150) were 65 years of age or older

— 5% (n=25) were 75 years of age or older
No differences in safety or effectiveness of SUTAB^® were observed between geriatric and younger patients²

IMPORTANT SAFETY INFORMATION

SUTAB^® IMPORTANT SAFETY INFORMATION

SUTAB^® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, for oral use

Indications and Usage
SUTAB is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

ADDITIONAL IMPORTANT SAFETY INFORMATION

Contraindications
SUTAB is contraindicated in the following conditions:

Gastrointestinal obstruction or ileus [see Warnings and Precautions (5.6)]
Bowel perforation [see Warnings and Precautions (5.6)]
Toxic colitis or toxic megacolon
Gastric retention
Hypersensitivity to any ingredient in SUTAB [see Warnings and Precautions (5.7) and Description (11)]

Warnings and Precautions

Serious Fluid and Electrolyte Abnormalities: Advise all patients to hydrate adequately before, during, and after the use of SUTAB. If a patient develops significant vomiting or signs of dehydration after taking SUTAB, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN). Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with SUTAB. Use SUTAB with caution in patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)].
Cardiac Arrhythmias: There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing SUTAB for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
Seizures: There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing SUTAB for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia [see Drug Interactions (7.1)].
Use in Patients with Risk of Renal Injury: Use SUTAB^® with caution in patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) [see Drug Interactions (7.1)]. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration with SUTAB and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Use in Specific Populations (8.6)].
Colonic Mucosal Ulcerations and Ischemic Colitis: Osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and SUTAB may increase these risks [see Drug Interactions (7.3)]. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).
Use in Patients with Significant Gastrointestinal Disease: If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering SUTAB [see Contraindications (4)].

Use with caution in patients with severe active ulcerative colitis.
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, rash, pruritus and urticaria have been reported with SUTAB [see Adverse Reactions (6.2)]. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should signs and symptoms occur.
Risk of Gastrointestinal Complications with Ingestion of Desiccant: Each SUTAB bottle contains a desiccant. Remove and discard the desiccant from both bottles of SUTAB the evening prior to the colonoscopy [see Dosage and Administration (2.2)]. Postmarketing reports of patients ingesting the desiccant along with the SUTAB tablets has been reported and may be associated with risk of gastrointestinal complications and/or choking.

Adverse Reactions
Most common gastrointestinal adverse reactions are nausea, abdominal distension, vomiting, and upper abdominal pain.

These are not all the possible side effects of SUTAB. Please see Adverse Reactions (6) in the Prescribing Information for a full list.

Drug Interactions
Drugs that increase risk of fluid and electrolyte imbalance. (7.1)

The Important Safety Information does not include all the information needed to use SUTAB safely and effectively. Please see accompanying full Prescribing Information for SUTAB.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.

SUTAB^® is a registered trademark of Azurity Pharmaceuticals, Inc.

PP-STB-6510-US-EN-v1

View the Full Prescribing Information and Medication Guide.

References: 1. IQVIA, National Prescription Audit Report. 2. SUTAB^® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 3. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi: 10.14309/ajg.0000000000001020. 4. Rex DK, Johnson DA, Anderson JC, et al; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739-750. 5. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174. 6. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 7. Data on file. Woburn, MA: Azurity Pharmaceuticals, Inc. 8. SUFLAVE^® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 9. SUPREP^® Bowel Prep Kit [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 10. Plenvu^® [package insert]. Bridgewater, NJ: Bausch Health LLC. 11. Clenpiq^® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc. 12. Rex DK, Di Palma JA, Rodriguez R, et al. A randomized clinical study comparing reduced-volume oral sulfate solution with standard 4-liter sulfate-free electrolyte lavage solution as preparation for colonoscopy. Gastrointest Endosc. 2010;72(2):328-336. 13. Matro R, Daskalakis C, Negoianu D, et al. Randomised clinical trial: polyethylene glycol 3350 with sports drink vs polyethylene glycol with electrolyte solution as purgatives for colonoscopy—the incidence of hyponatraemia. Aliment Pharmacol Ther. 2014;40(6):610-619.

SUFLAVE^® IMPORTANT SAFETY INFORMATION

SUFLAVE^® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution)

Indications and Usage
SUFLAVE is indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

ADDITIONAL IMPORTANT SAFETY INFORMATION

Contraindications
SUFLAVE is contraindicated in the following conditions:

Gastrointestinal obstruction or ileus [see Warnings and Precautions (5.6)]
Bowel perforation [see Warnings and Precautions (5.6)]
Toxic colitis or toxic megacolon
Gastric retention
Hypersensitivity to any ingredient in SUFLAVE [see Warnings and Precautions (5.8)]

Warnings and Precautions

Serious Fluid and Electrolyte Abnormalities: Advise all patients to hydrate adequately before, during, and after the use of SUFLAVE. If a patient develops significant vomiting or signs of dehydration after taking SUFLAVE, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN).

Bowel preparation products can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment [see Adverse Reactions (6.2)]. Correct fluid and electrolyte abnormalities before treatment with SUFLAVE. Use SUFLAVE with caution in patients with conditions, or who are using medications [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)], that increase the risk for fluid and electrolyte disturbances or may increase the risk of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)].
Cardiac Arrhythmias: There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. Use caution when prescribing SUFLAVE for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT interval, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
Seizures: There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing SUFLAVE for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia [see Drug Interactions (7.1)].
Use in Patients with Risk of Renal Injury: Use SUFLAVE with caution in patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) [see Drug Interactions (7.1)]. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration with SUFLAVE and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Use in Specific Populations (8.6)].
Colonic Mucosal Ulcerations and Ischemic Colitis: Osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and SUFLAVE may increase these risks [see Drug Interactions (7.3)]. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease.
Use in Patients with Significant Gastrointestinal Disease: If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering SUFLAVE [see Contraindications (4)].

Use with caution in patients with severe active ulcerative colitis.
Aspiration: Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of SUFLAVE. Observe these patients during administration of SUFLAVE.

Do not combine SUFLAVE with starch-based thickeners [see Dosage and Administration (2.1)]. Polyethylene glycol (PEG), a component of SUFLAVE, when mixed with starch-thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG-based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.
Hypersensitivity Reactions: SUFLAVE contains polyethylene glycol (PEG) and other ingredients that may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus [see Adverse Reactions (6.2)]. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur.

Adverse Reactions
Most common adverse reactions (≥2%) are: nausea, abdominal distension, vomiting, abdominal pain and headache.

These are not all the possible side effects of SUFLAVE. Please see Adverse Reactions (6) in the Prescribing Information for a full list.

Drug Interactions
Drugs that increase risk of fluid and electrolyte imbalance. (7.1)

The Important Safety Information does not include all the information needed to use SUFLAVE safely and effectively. Please see accompanying full Prescribing Information for SUFLAVE.

To Report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.

SUFLAVE^® is a registered trademark of Azurity Pharmaceuticals, Inc.

PP-SUF-6488-US-EN-v1

View the Full Prescribing Information and Medication Guide.

References: 1. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 2. SUTAB^® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 3. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi:10.14309/ajg.0000000000001020 4. SUFLAVE^® [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc. 5. Bhandari R, Goldstein M, Mishkin DS, et al. Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy. J Clin Gastroenterol. 2023;57(9):920-927. doi:10.1097/MCG.0000000000001894